300
Participants
Start Date
September 22, 2023
Primary Completion Date
September 22, 2025
Study Completion Date
September 22, 2025
Massachusetts General Hospital, Boston
Collaborators (2)
AstraZeneca
INDUSTRY
Novartis
INDUSTRY
Massachusetts General Hospital
OTHER